ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

doi:10.3324/haematol.2023.282921

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.

Haematologica - 1 May 2024

Riabov Vladimir, Xu Qingyu, Schmitt Nanni, Streuer Alexander, Ge Guo, Bolanos Lyndsey, Wunderlich Mark, Jann Johann-Christoph, Wein Alina, Altrock Eva, Demmerle Marie, Mukherjee Sanjay, Ali Abdullah Mahmood, Rapp Felicitas, Nowak Verena, Weimer Nadine, Obländer Julia, Palme Iris, Göl Melda, Jawhar Ahmed, Darwich Ali, Wuchter Patrick, Weiss Christel, Raza Azra, Foulks Jason M, Starczynowski Daniel T, Yang Feng-Chun, Metzgeroth Georgia, Steiner Laurenz, Jawhar Mohamad, Hofmann Wolf-Karsten, Nowak Daniel

Abstract excerpt

Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor and indirect transcriptional repressor of the anti-apoptotic factor MCL-1, has previously shown clinical activity in AML....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Piperidines

Share to Repressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 37916386
DOI: 10.3324/haematol.2023.282921
PMCID: PMC11063838

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.PMID 37916386Read ↗

Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.Semantic proximity Read ↗

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesSemantic proximity Read ↗

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Semantic proximity Read ↗

Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.Semantic proximity Read ↗

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?Semantic proximity Read ↗

MCL1 dependence across MDS subtypes and dual inhibition of MCL1 and BCL2 in MISTRG6 miceSemantic proximity Read ↗

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.Semantic proximity Read ↗

Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.Semantic proximity Read ↗

SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.Semantic proximity Read ↗

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromesSemantic proximity Read ↗

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLSemantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.